Loading…
Traded Oct 2, 2025 · Filed Oct 6, 2025
Incyte's & General Counsel sold $53K of Incyte shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$52,502
Shares × reported transaction price
65 days after results of Jul 29, 2025, 26 days before results of Oct 28, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $86.28 on Oct 2, 2025, within 1% of its 52-week high, little changed over the previous 30 trading days
52-week range $55.17 (Apr 10, 2025) to $86.96 (Sep 3, 2025), 98% of the way up, from 250 adjusted closes. 30 trading days earlier: $86.20 on Aug 20, 2025. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Opzelura on Sep 18, 2025, 14 days before this trade.
New use approved (efficacy supplement). Active ingredient: Ruxolitinib Phosphate. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −1.4% | −1.0% | −0.4% |
| 30 days | +20.7% | +0.2% | +20.5% |
| 90 days | +16.8% | +2.8% | +14.0% |
| 180 days | +8.8% | −1.5% | +10.3% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.